Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Clearmind Medicine Inc (NQ: CMND ) 1.660 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 1.660 Bid (Size) 1.580 (1) Ask (Size) 1.780 (1) Prev. Close 1.660 Today's Range 1.660 - 1.660 52wk Range 0.9205 - 16.19 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product July 19, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Nasdaq Edges Lower; Morgan Stanley Earnings Top Views July 16, 2024 Via Benzinga Performance YTD -40.29% -40.29% 1 Month +23.88% +23.88% 3 Month +37.19% +37.19% 6 Month +44.34% +44.34% 1 Year -87.15% -87.15% More News Read More Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session July 16, 2024 Via Benzinga CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024 June 17, 2024 Via InvestorPlace Crude Oil Down 1%; Bank of America Posts Upbeat Earnings July 16, 2024 Via Benzinga Exposures Fossil Fuels Why Is SciSparc (SPRC) Stock Up 25% Today? July 16, 2024 Via InvestorPlace Topics Intellectual Property Exposures Intellectual Property Dow Jumps 400 Points; US Retail Sales Flat For June July 16, 2024 Via Benzinga Topics Stocks Exposures US Equities Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism July 16, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss July 16, 2024 From Clearmind Medicine Inc. Via GlobeNewswire SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss July 16, 2024 From SciSparc Ltd Via GlobeNewswire Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference July 12, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher June 28, 2024 Via Benzinga Topics Intellectual Property Exposures Intellectual Property Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment June 28, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Day Trading My Way From Red To Green June 23, 2024 Via Talk Markets Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment June 20, 2024 From Clearmind Medicine Inc. Via GlobeNewswire What's Going On With Clearmind Medicine Stock Tuesday? June 11, 2024 Via Benzinga Topics Intellectual Property Exposures Intellectual Property Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink June 11, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product May 10, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Why Clearmind Medicine Stock Is Moving Higher May 07, 2024 Via Benzinga Topics Intellectual Property Exposures Intellectual Property Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 07, 2024 Via Benzinga Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment May 07, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Applies to Cease Being a Reporting Issuer in Canada April 30, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More April 17, 2024 Via Benzinga Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More April 17, 2024 Via Benzinga Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders April 17, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
